Milestone Pharmaceuticals Inc. 8K

Milestone Pharmaceuticals reported Q2 2026 results showing early revenue and expanded coverage for CARDAMYST, opened its Phase 3 AFib-RVR trial, and ended the quarter with $170.6 million in cash providing runway into H2 2027 despite higher launch-related losses.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) reported its unaudited second quarter 2026 financial results and corporate update, highlighting early commercial progress of CARDAMYST (etripamil) nasal spray for PSVT, including growth to more than 800 prescribers, over 1,500 prescriptions filled, and a sharp increase in U.S. commercial insurance coverage to about 50% of lives following new formulary wins such as UnitedHealthcare. The company noted ongoing global regulatory reviews for etripamil in Europe and China, activation of clinical sites and opening of enrollment for the Phase 3 ReVeRA-301 trial in atrial fibrillation with rapid ventricular rate (AFib-RVR), and recent supportive scientific publications and conference activity. Financially, Milestone ended June 30, 2026 with $170.6 million in cash, cash equivalents and short-term investments, guiding that this provides runway into the second half of 2027, while reporting Q2 2026 product revenue of $0.6 million, increased SG&A spend tied to the U.S. launch of CARDAMYST, and a net loss of $28.6 million for the quarter. The company also announced details of an investor conference call and webcast to discuss the results.

Filing Facts

CIK

1408443

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-094466

Alert Tier

6